Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.56 USD
Change Today -0.03 / -5.08%
Volume 2.3M
As of 8:10 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

cytori therapeutics inc (CYTX) Snapshot

Open
$0.61
Previous Close
$0.59
Day High
$0.61
Day Low
$0.55
52 Week High
07/7/14 - $2.52
52 Week Low
11/12/14 - $0.36
Market Cap
84.5M
Average Volume 10 Days
2.9M
EPS TTM
$-0.56
Shares Outstanding
150.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYTORI THERAPEUTICS INC (CYTX)

cytori therapeutics inc (CYTX) Related Bloomberg News

View More Bloomberg News

cytori therapeutics inc (CYTX) Related Businessweek News

View More BusinessWeek News

cytori therapeutics inc (CYTX) Details

Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy consisting of a heterogeneous population of specialized cells, including stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury. It also offers Celution System devices and consumable sets, and other ancillary products for the customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan, and other regions. The company markets its products to hospitals, clinics, tissue banks, and stem cell banking companies through direct sales representatives, distributors, and partners worldwide. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

78 Employees
Last Reported Date: 03/16/15
Founded in 1996

cytori therapeutics inc (CYTX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $437.4K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $79.1K
President of Asia Pacific
Total Annual Compensation: $367.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2014.

cytori therapeutics inc (CYTX) Key Developments

Cytori Therapeutics, Inc.’s Preclinical Data for the Treatment of Thermal Injury Published in the Journal Burns

Cytori Therapeutics, Inc. announced that preclinical and mechanistic data from its thermal injury study, performed with support from the Biomedical Advanced Research and Development Authority (BARDA), was published in the journal Burns, the official journal of the American Burn Association. This paper reports that seeding Cytori Cell Therapy™ onto a widely used dermal substitute led to improvement in a number of parameters of healing of full thickness burns. Specifically, histopathological assessment demonstrated that the average depth of tissue within the wound was increased by approximately 2-fold in animals treated with Cytori Cell Therapy. This was associated with an increase in collagen deposition (1.7-fold), blood vessel density (1.5-fold), and mean vessel area (1.8-fold). Immunohistochemical analysis revealed an increase in the number of vessels expressing a-SMA (a marker for mature blood vessels) in animals treated with Cytori’s Cell Therapy. Taken together, these results demonstrate that seeding Cytori Cell Therapy onto this scaffold promotes blood vessel maturation. Finally, the findings showed increased vascularity (1.5-fold) and cellularity (1.45-fold) of the dermal substitute itself. Use of skin substitutes provides an important option for care of patients with larger burns who cannot undergo definitive wound coverage in a single procedure. Such options will be particularly important following a mass casualty event that could overwhelm the capacity of specialist burn care centers. In this context a considerable portion of burn care will likely have to be provided by medical personnel without specialist burn surgery experience. This research, funded by a contract from the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services, will be included in an Investigational Device Exemption (IDE) package to be submitted to FDA for a proposed clinical trial using Cytori Cell Therapy in thermal burn injury. While there has been tremendous improvement in survival following severe thermal burn injury, hospitalization time, the development of scarring with pain and restricted range of motion, and other problems at both the injury and skin graft donor site remain significant issues. Autologous cell therapies such as those offered by Cytori have the potential to improve the quality and rate of wound healing and reduce scarring. In addition, during a mass casualty event, availability of specialized burn centers for burn injuries may be limited and alternative therapeutic approaches will likely be required. Therefore, autologous Cytori’s Cell Therapy represents a novel medical countermeasure not only to address these challenges but also to promote wound healing and tissue repair and improve casualty care.

Cytori Therapeutics, Inc. Receives A Letter From The Listing Qualifications Staff Of The NASDAQ Stock Market LLC

On June 4, 2015, Cytori Therapeutics, Inc. received a letter from the Listing Qualifications staff of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5450(a)(1). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a period of 180 calendar days, or until December 1, 2015, in which to regain compliance. In order to regain compliance with the minimum bid price requirement, the closing bid price of the Company’s common stock must be at least $1 per share for a minimum of ten consecutive business days during this 180-day period. In the event that the Company does not regain compliance within this 180-day period, the Company may be eligible to seek an additional compliance period of 180 calendar days if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Global Market, with the exception of the bid price requirement, and provides written notice to Nasdaq of its intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Nasdaq Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice to the Company that its common stock will be subject to delisting. The Notice does not result in the immediate delisting of the Company’s common stock from the Nasdaq Global Market. The Company intends to monitor the closing bid price of the Company’s common stock to allow a reasonable period for the price to rebound from its recent decline but will continue to consider its available options to regain compliance. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or maintain compliance with the other listing requirements.

Cytori Therapeutics, Inc. Enters into $17,700,000 Loan and Security Agreement with Oxford Finance LLC

On May 29, 2015, Cytori Therapeutics, Inc. entered into a Loan and Security Agreement with Oxford Finance LLC, as collateral agent and lender and the other lenders party thereto from time to time, pursuant to which Oxford agreed to make a term loan to the company in an aggregate principal amount of $17,700,000. In connection with securing the Loan Facility, the company prepaid all outstanding amounts under its Loan and Security Agreement, dated June 28, 2013, with Oxford Finance LLC and Silicon Valley Bank. The Term Loan accrues interest at a floating rate equal to the three-month LIBOR rate (with a floor of 1.00%) plus 7.95% per annum. The company is required to make interest-only payments through June 1, 2016, and starting on July 1, 2016, the company is required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through June 1, 2019, the maturity date. As security for its obligations under the Loan Agreement, the company granted a security interest in substantially all of its existing and after-acquired assets, subject to certain exceptions set out in the Loan Agreement and excluding its intellectual property assets, which are subject to a negative pledge by the company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTX:US $0.56 USD -0.03

CYTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.18 USD -0.08
Caladrius Biosciences Inc $1.88 USD +0.01
International Stem Cell Corp $0.04 USD -0.0023
Nuo Therapeutics Inc $0.21 USD -0.003
StemCells Inc $0.50 USD -0.084
View Industry Companies
 

Industry Analysis

CYTX

Industry Average

Valuation CYTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTORI THERAPEUTICS INC, please visit www.cytori.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.